Key insider transaction
Shannon L. Devers, who serves as Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals (NASDAQ: IONS), completed the sale of 20,006 shares of common stock on March 3, 2026. The disposition generated roughly $1.59 million, with executed prices ranging from $79.115 to $80.837 per share.
Concurrent option exercise
In conjunction with that sale, Devers exercised options to acquire 20,006 shares of Ionis common stock. The exercise prices ranged from $32.6 to $52.87, producing an aggregate cash outlay of $723,254 to acquire those shares prior to the subsequent sale.
Stock performance context
Per InvestingPro data, Ionis shares have risen approximately 123% over the past year. Despite that strong year-to-date performance, the stock has retreated from recent highs and was trading at $75.16 at the time referenced in the data cited.
Regulatory and clinical catalysts
On the regulatory front, Ionis announced that the U.S. Food and Drug Administration has accepted a supplemental New Drug Application for olezarsen and granted it Priority Review status. The application targets treatment of severe hypertriglyceridemia, and the FDA assigned a target action date of June 30, 2026. The Priority Review follows Phase 3 trial results reporting meaningful reductions in triglyceride levels and fewer acute pancreatitis events.
Separately, Ionis will present new clinical data on DAWNZERA, a therapy for hereditary angioedema, at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting.
Analyst activity and outlook
Analyst coverage of Ionis has been active. Bernstein SocGen Group increased its price target to $90 and cited upcoming Phase 3 readouts as potential catalysts. Stifel lifted its price target to $77, while noting that Ionis' 2026 topline guidance fell short of expectations. Morgan Stanley raised its price target to $95, calling out strong commercial execution in the fourth quarter of 2025 even as guidance for 2026 came in lower than anticipated.
What this collection of developments shows
The insider transaction coincides with a period of heightened attention on Ionis' clinical and commercial progress. The combination of a significant insider exercise and sale, an FDA Priority Review for a late-stage asset, upcoming scientific presentations, and multiple analyst target revisions underscores active engagement among company leadership, regulators, and market analysts. Observers should note the coexistence of strong recent stock performance with a pullback from recent highs and mixed signals in company guidance versus execution.
Note: Data points and timelines referenced in this article reflect information presented regarding the insider transaction, clinical programs, and analyst commentary. No additional events or claims have been added beyond what was reported.